RedHill Biopharma (RDHL) Other financing activities (2014 - 2023)

RedHill Biopharma (RDHL) has reported Other financing activities for 9 consecutive years, with $1.9 million the latest figure, recorded in Q2 2023.

• On a quarterly basis, Other financing activities rose 196.26% year-over-year to $1.9 million in Q2 2023; TTM through Jun 2023 was -$4.6 million, a 281.11% decrease from a year earlier, with the FY2025 full-year figure at $2.0 million, up 153.16% from the prior year.
• Other financing activities was $1.9 million for Q2 2023 at RedHill Biopharma, down from $5.0 million in the prior quarter.
• Over five years, Other financing activities peaked at $5.0 million in Q1 2023 and troughed at -$20.0 million in Q1 2020.
• A 4-year average of -$1.9 million and a median of $389500.0 in 2021 frame the typical range for Other financing activities.
• Across the five-year window, Other financing activities tumbled 1837.72% in 2022 and surged 196.26% in 2023, its largest moves.
• Over 4 years, Other financing activities stood at $4.0 million in 2020, then tumbled by 83.38% to $665000.0 in 2021, then tumbled by 1347.82% to -$8.3 million in 2022, then soared by 122.98% to $1.9 million in 2023.
• The last three Other financing activities figures came in at $1.9 million (Q2 2023), $5.0 million (Q1 2023), and -$8.3 million (Q4 2022), per Business Quant data.